9119 POSTER Combination of Pertuzumab and Erlotinib as 2nd-/3rd-Line (2/3L) Treatment for Patients (pts) With Metastatic Non-Small Cell Lung Cancer (NSCLC) – Safety and Anti-Tumour Activity by FDG-PET/CT Imaging Changes
Saved in:
| Title: | 9119 POSTER Combination of Pertuzumab and Erlotinib as 2nd-/3rd-Line (2/3L) Treatment for Patients (pts) With Metastatic Non-Small Cell Lung Cancer (NSCLC) – Safety and Anti-Tumour Activity by FDG-PET/CT Imaging Changes |
|---|---|
| Authors: | Hughes, B., Mileshkin, L., Townley, P., Gitlitz, B., Eaton, K., Mitchell, P., Hicks, R., Loecke, D., Amler, L., Pirzkall, A. |
| Source: | European Journal of Cancer. Sep2011 Supplement 1, Vol. 47, pS629-S629. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09598049 |
|---|---|
| DOI: | 10.1016/S0959-8049(11)72431-5 |
